Literature DB >> 15248156

Recombinant viruses as tools to induce protective cellular immunity against infectious diseases.

Carolina Damas Rocha1, Braulia Costa Caetano, Alexandre Vieira Machado, Oscar Bruna-Romero.   

Abstract

Infections by intracellular pathogens such as viruses, some bacteria and many parasites, are cleared in most cases after activation of specific T cellular immune responses that recognize foreign antigens and eliminate infected cells. Vaccines against those infectious organisms have been traditionally developed by administration of whole live attenuated or inactivated microorganisms. Nowadays, research is focused on the development of subunit vaccines, containing the most immunogenic antigens from the particular pathogen. However, when purified subunit vaccines are administered using traditional immunization protocols, the levels of cellular immunity induced are mostly low and not capable of eliciting complete protection against diseases caused by intracellular microbes. In this review, we present a promising alternative to those traditional protocols, which is the use of recombinant viruses encoding subunit vaccines as immunization tools. Recombinant viruses have several interesting features that make them extremely efficient at inducing immune responses mediated by T-lymphocytes. This cellular immunity has recently been demonstrated to be of key importance for protection against malaria and AIDS, both of which are major targets of the World Health Organization for vaccine development. Thus, this review will focus in particular on the development of new vaccination protocols against these diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15248156

Source DB:  PubMed          Journal:  Int Microbiol        ISSN: 1139-6709            Impact factor:   2.479


  22 in total

Review 1.  Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines.

Authors:  Lena Serghides; Mariana Vidric; Tania H Watts
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  Recombinant canarypox virus expressing the VP2 protein of infectious bursal disease virus induces protection in vaccinated SPF chickens.

Authors:  Flavia Adriana Zanetti; Romina Cardona; Carlos Rodolfo Federico; Silvina Chimeno-Zoth; Gabriela Calamante
Journal:  Virol Sin       Date:  2016-06       Impact factor: 4.327

3.  Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.

Authors:  Kristina E Rehm; Rachel L Roper
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

4.  Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.

Authors:  V Ann Stewart; Shannon M McGrath; Patrice M Dubois; Maria G Pau; Pascal Mettens; Joseph Shott; Michelle Cobb; J Robert Burge; David Larson; Lisa A Ware; Marie-Ange Demoitie; Gerrit Jan Weverling; Babak Bayat; Jerome H H V Custers; Marie-Claude Dubois; Joe Cohen; Jaap Goudsmit; D Gray Heppner
Journal:  Infect Immun       Date:  2007-02-16       Impact factor: 3.441

5.  A human dendritic cell subset receptive to the Venezuelan equine encephalitis virus-derived replicon particle constitutively expresses IL-32.

Authors:  Kevin P Nishimoto; Amanda K Laust; Edward L Nelson
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

6.  Polarization of protective immunity induced by replication-incompetent adenovirus expressing glycoproteins of pseudorabies virus.

Authors:  Young Woo Han; Abi G Aleyas; Junu A George; Seon Ju Kim; Hye Kyung Kim; Hyun A Yoon; Dong Jin Yoo; Seong Ho Kang; Koanhoi Kim; Seong Kug Eo
Journal:  Exp Mol Med       Date:  2008-12-31       Impact factor: 8.718

7.  Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).

Authors:  Rachael Chiam; Emma Sharp; Sushila Maan; Shujing Rao; Peter Mertens; Barbara Blacklaws; Nick Davis-Poynter; James Wood; Javier Castillo-Olivares
Journal:  PLoS One       Date:  2009-06-22       Impact factor: 3.240

8.  Construction and preparation of three recombinant adenoviruses expressing truncated NS3 and core genes of hepatitis C virus for vaccine purposes.

Authors:  Seyed Younes Hosseini; Farzaneh Sabahi; Seyed Mohammad Moazzeni; Mohammad Hossein Modarressi; Mehdi Saberi Firoozi; Mehrdad Ravanshad
Journal:  Hepat Mon       Date:  2012-08-14       Impact factor: 0.660

9.  Recombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1.

Authors:  Érica Araújo Mendes; Flavio G Fonseca; Bárbara M Casério; Janaína P Colina; Ricardo Tostes Gazzinelli; Braulia C Caetano
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

10.  TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.